| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.2 |
| Net income | -18.3 | -25.7 |
| EPS (diluted, $ a share) | $-7.43 | $-10.60 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ATYR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
aTYR Pharma INC: key numbers
- Share price
- $5.24Close, Nov 16
- Market cap
- $13.4M
- Shares outstanding
- 2.55MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from aTYR Pharma INC
All →aTYR Pharma Nasdaq/NYSE Compliance Notice
aTyr Pharma has regained compliance with Nasdaq's minimum bid price requirement after its common stock closed at or above $1.00 per share for 10 consecutive business days. The company had previously been under a deficiency notice since December 2025 and was granted an extension until November 30, 2026, to meet the standard. As of this filing, the company has no outstanding deficiency notices from Nasdaq.
- Counterparty
- Nasdaq
aTYR Pharma Capital Raise
aTyr Pharma, Inc. filed a prospectus supplement to establish an at-the-market (ATM) offering program for the sale of up to $79,994,251 of its common stock. The sales will be conducted through Jefferies LLC as the sales agent under an existing Open Market Sale Agreement. This filing allows the company to raise equity capital from time to time at prevailing market prices.
- Counterparty
- Jefferies LLC
aTYR Pharma Financial Results
aTyr Pharma reported third quarter 2026 financial results, ending the period with $50.3 million in cash and investments, providing a runway into late 2028. The company reached alignment with the FDA on a Phase 3 study protocol for efzofitimod in pulmonary sarcoidosis and is prioritizing strategic partnerships to advance the program.
“During the last quarter we reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of our lead therapeutic candidate, efzofitimod, in pulmonary sarcoidosis patients with restrictive lung disease, a major form of interstitial lung disease (ILD) with a high unmet medical need. We believe the efzofitimod program is well-positioned, considering the late-stage development status in an indication with a multi-billion-dollar global market opportunity, and have determined that at this time the best way for us to advance efzofitimod is to prioritize strategic partnerships.”
Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer
aTYR Pharma Reverse Stock Split
aTyr Pharma filed a Certificate of Amendment to effect a 1-for-40 reverse stock split of its common stock, effective October 28, 2026. The split will reduce the number of outstanding shares from approximately 100.5 million to 2.5 million to meet exchange requirements. Trading on a split-adjusted basis will begin on The Nasdaq Capital Market on October 29, 2026.
aTYR Pharma Reverse Stock Split
aTyr Pharma stockholders approved a proposal at a special meeting to authorize the Board of Directors to effect a reverse stock split of the company's common stock. The approved ratio range is between 1-for-10 and 1-for-50, with the final ratio to be determined at the Board's discretion.
aTYR Pharma Business Update
aTyr Pharma reached alignment with the FDA on the protocol for a new Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The global study is expected to enroll approximately 372 patients and initiate study-related activities in the fourth quarter of 2026.
- Counterparty
- FDA
- Term
- 54 weeks